全文获取类型
收费全文 | 2895篇 |
免费 | 242篇 |
国内免费 | 106篇 |
专业分类
耳鼻咽喉 | 19篇 |
儿科学 | 21篇 |
妇产科学 | 43篇 |
基础医学 | 208篇 |
口腔科学 | 17篇 |
临床医学 | 309篇 |
内科学 | 336篇 |
皮肤病学 | 29篇 |
神经病学 | 40篇 |
特种医学 | 67篇 |
外科学 | 330篇 |
综合类 | 256篇 |
预防医学 | 135篇 |
眼科学 | 9篇 |
药学 | 319篇 |
2篇 | |
中国医学 | 17篇 |
肿瘤学 | 1086篇 |
出版年
2024年 | 20篇 |
2023年 | 100篇 |
2022年 | 204篇 |
2021年 | 225篇 |
2020年 | 218篇 |
2019年 | 191篇 |
2018年 | 177篇 |
2017年 | 195篇 |
2016年 | 184篇 |
2015年 | 182篇 |
2014年 | 339篇 |
2013年 | 210篇 |
2012年 | 218篇 |
2011年 | 203篇 |
2010年 | 103篇 |
2009年 | 117篇 |
2008年 | 117篇 |
2007年 | 78篇 |
2006年 | 51篇 |
2005年 | 41篇 |
2004年 | 14篇 |
2003年 | 14篇 |
2002年 | 6篇 |
2001年 | 8篇 |
2000年 | 6篇 |
1999年 | 2篇 |
1998年 | 3篇 |
1997年 | 2篇 |
1996年 | 3篇 |
1995年 | 3篇 |
1993年 | 3篇 |
1992年 | 1篇 |
1991年 | 2篇 |
1990年 | 1篇 |
1989年 | 1篇 |
1988年 | 1篇 |
排序方式: 共有3243条查询结果,搜索用时 453 毫秒
81.
Youn Jin Choi Jungyoon Ho Ahwon Lee Soo Young Hur Hyeon-Chun Park Jong Sup Park Yeun-Jun Chung Sug Hyung Lee 《Pathology, research and practice》2018,214(8):1231-1233
Concurrence of both endometrial adenocarcinoma and ovarian adult granulosa cell tumor (aGCT) is believed to be related to high estrogen milieu, but genomic alterations of the concurrent endometrial adenocarcinoma and aGCT are not known. For this, we analyzed an uterine endometrial adenocarcinoma and an ovarian aGCT in a same patient by a targeted next generation sequencing (NGS). We found a germline mutation in STK11 (p.L113fs). The endometrial adenocarcinoma harbored FGFR2 and TP53 mutations and the aGCT harbored a FOXL2 (p.C134?W) mutation. These germline and somatic mutations have been reported in non-concurrent tumors. These two tumors harbored 20 CNAs but only one CNA was exactly overlapped in the tumors. Our findings indicate that the concurrent endometrial adenocarcinoma and aGCT in this patient might not be genetically related to each other at germline or somatic level and suggest that such concurrence might be originated from non-genetic backgrounds including stimulated estrogen milieu. 相似文献
82.
83.
肿瘤治疗过程中会出现很多严重的不良反应,如何将药物特异性导向癌细胞就成为了肿瘤治疗中亟需解决的问
题。外泌体是由细胞分泌的、纳米级别的、双层脂质的盘状囊泡结构。正常细胞与肿瘤细胞均可分泌外泌体,供体细胞分泌的
外泌体携带着蛋白质、脂质和核糖核酸(包括microRNA和lncRNA),可直接被同组织内其周围的受体细胞所吸收;同时外泌体
几乎存在于唾液、血液、尿液、脑脊髓液等所有体液中,通过体液运输被不同组织内受体细胞所吸收,为受体细胞的生长提供必
要的营养物质。肿瘤细胞中往往可对外释放出高于正常组织的外泌体,在肿瘤发展过程中外泌体对肿瘤的生长、转移和血管
生成起到重要的作用;同时癌细胞所分泌的外泌体中有着可用来区别与其他细胞外泌体不同的特征性分子,可作为肿瘤临床
诊断的分子标志物,也可作为肿瘤分级、精准治疗及预后评估的重要依据。鉴于此,本文收集国外内相关研究资料,对外泌体
的生物学特征进行总结,并综述了其在临床肿瘤诊断、治疗中的作用及应用潜力,并对外泌体进一步的发展方向进行展望,以
期能为外泌体在临床肿瘤精准治疗中的应用提供理论支持。 相似文献
84.
Gastric cancer is the second leading cause of cancerrelated deaths worldwide.Conventional cytotoxic chemotherapy has limited efficacy for metastatic gastric cancer,with an overall survival of approximately ten months.Recent advances in high-throughput technologies have enabled the implementation of personalized cancer therapy for high-risk patients.The use of such high-throughput technologies,including microarray and next generation sequencing,have promoted the discovery of novel targets that offer new treatment strategies for patients lacking other therapeutic options.Many molecular pathways are currently under investigation as therapeutic targets in gastric cancer,including those related to the epidermal growth factor receptor family,the mesenchymal-epithelial transition factor axis,and the phosphatidylinositol 3-kinase-AKTmammalian target of rapamycin factors.Advances in molecular diagnostic tools further support the discovery of new molecular targets.Limitations exist,however;not all patients can be tested for biomarkers,and numerous challenges hamper implementation of targeted therapy in clinical settings.Indeed,the scale of tumor genomic profiling is rapidly outpacing our ability to appropriately synthesize all the information in order to optimally refine patient care.Therefore,clinicians must continue to educate themselves regarding new tools and frameworks,and to utilize multidisciplinary team science,comprised of oncologists,geneticists,pathologists,biologists and bioinformaticians,to successfully implement this genomic approach therapeutically. 相似文献
85.
Bisulfite conversion of genomic DNA combined with next-generation sequencing (NGS) has become a very effective approach for mapping the whole-genome and sub-genome wide DNA methylation landscapes. However, whole methylome shotgun bisulfite sequencing is still expensive and not suitable for analyzing large numbers of human cancer specimens. Recent advances in the development of targeted bisulfite sequencing approaches offer several attractive alternatives. The characteristics and applications of these methods are discussed in this review article. In addition, the bioinformatic tools that can be used for sequence capture probe design as well as downstream sequence analyses are also addressed. 相似文献
86.
87.
Niek G.J. Leus Henriëtte W.M. Morselt Peter J. Zwiers Piotr S. Kowalski Marcel H.J. Ruiters Grietje Molema Jan A.A.M. Kamps 《International journal of pharmaceutics》2014
In recent years much research in RNA nanotechnology has been directed to develop an efficient and clinically suitable delivery system for short interfering RNA (siRNA). The current study describes the in vivo siRNA delivery using PEGylated antibody-targeted SAINT-based-lipoplexes (referred to as antibody-SAINTPEGarg/PEG2%), which showed superior siRNA delivery capacity and effective down-regulation of VE-cadherin gene expression in vitro in inflammation-activated primary endothelial cells of different vascular origins. PEGylation of antibody-SAINTPEGarg resulted in more desirable pharmacokinetic behavior than that of non-PEGylated antibody-SAINTPEGarg. To create specificity for inflammation-activated endothelial cells, antibodies against vascular cell adhesion molecule-1 (VCAM-1) were employed. In TNFα-challenged mice, these intravenously administered anti-VCAM-1-SAINTPEGarg/PEG2% homed to VCAM-1 protein expressing vasculature. Confocal laser scanning microscopy revealed that anti-VCAM-1-SAINTPEGarg/PEG2% co-localized with endothelial cells in lung postcapillary venules. Furthermore, they did not exert any liver and kidney toxicity. Yet, lack of in vivo gene silencing as assessed in whole lung and in laser microdissected lung microvascular segments indicates that in vivo internalization and/or intracellular trafficking of the delivery system and its cargo in the target cells are not sufficient, and needs further attention, emphasizing the essence of evaluating siRNA delivery systems in an appropriate in vivo animal model at an early stage in their development. 相似文献
88.
89.
《Cancer radiothérapie》2015,19(1):10-15
The first step in the diagnosis of a metastatic brain lesion is to exclude a primary central nervous sytem tumour, followed by verification or identification of the primary tumor site, in order to guide the clinician to specific therapy. In addition to morphological features, ancillary immunohistochemical study is most effective for the evaluation of a metastatic neoplasm of unknown primary. Although the main principles are same, there are slight variations in the approach to the secondary lesion in the central nervous system versus other regions. Indeed, immunohistochemical approach focuses on the most common tumor types associated with secondary brain colonization: lung cancer, breast cancer and melanoma. Several studies have reported that targeted therapies are capable of reducing brain metastases in melanoma or non-small cell lung cancer, sometimes with a high dramatic response. These results have clearly impacted routine neuropathological practice. It is likely that molecular subtyping of central nervous system metastases will play an increasing role in the future. In accordance with the recommendations of Inca (French national cancer institute), the pathologist develops appropriate strategies for molecular and immunohistochemical analysis, in order to provide results as soon as possible. This article summarizes the diagnosic approach to brain metastases, with a focus on the recent emergence of targeted therapies. 相似文献
90.
《Best Practice & Research: Clinical Gastroenterology》2014,28(5):831-842
Molecular profiling of hepatocellular carcinoma (HCC) is enabling the advancement of novel approaches to disease diagnosis and management. Accurate prognosis prediction in HCC is specially critical. Clinical staging systems for HCC support clinical decision-making (e.g., BCLC algorithm) might be complemented by molecular-based information in the near future. Molecular signatures derived from tumour and non-tumour samples are associated with patient recurrence an outcome. Single nucleotide polymorphisms have been linked with HCC development. Next generation sequencing studies have brought to light the genomic diversity of this disease. Gens recurrently altered in HCC and susceptible to be targeted belong to signalling pathways including telomere maintenance, cell cycle, chromatin remodelling, Wnt/beta-catenin, RAS/RAF/MAPK and PI3K/AKT/mTOR pathways. Oncogenic loops are unknown but might include some of the already discovered aberrations. Despite the intratumoral heterogeneity observed in HCC tumours, studies including large number of samples can identify key genetic drivers and contribute to the development of novel treatments and a personalized medicine. 相似文献